Insmed Inc. (INSM) announced that it priced an underwritten public offering of about 7.81 million shares of its common stock at a price to the public of $96.00 per share.
The company expects gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, to be approximately $750 million. In addition, Insmed has granted the underwriters a 30-day option to purchase up to an additional 1.17 million shares of common stock.
Insmed said it plans to use the net proceeds from this offering to fund continued research and development of brensocatib as well as pre-commercial and, if approved, commercialization activities related to brensocatib, activities related to the further commercialization and development of ARIKAYCE (amikacin liposome inhalation suspension), further research and development of treprostinil palmitil inhalation powder (TPIP), INS1201, and the Company's pre-clinical research product candidates, and for other general corporate purposes, including business expansion activities.
Goldman Sachs & Co. LLC, Leerink Partners, BofA Securities, Jefferies and J.P. Morgan are acting as joint book-running managers for the offering. Stifel is acting as co-lead manager for the offering.
The offering is expected to close on June 13, 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.